as of 12-12-2025 3:44pm EST
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 424.4M | IPO Year: | 2023 |
| Target Price: | $8.00 | AVG Volume (30 days): | 980.8K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $11.57 | Next Earning Date: | 11-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
See Remarks
Avg Cost/Share
$2.68
Shares
114,703
Total Value
$307,025.52
Owned After
0
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$2.61
Shares
1,915,700
Total Value
$4,999,977.00
Owned After
6,046,907
SEC Form 4
10% Owner
Avg Cost/Share
$2.61
Shares
1,915,700
Total Value
$4,999,977.00
Owned After
6,046,907
SEC Form 4
10% Owner
Avg Cost/Share
$2.61
Shares
1,915,700
Total Value
$4,999,977.00
Owned After
6,046,907
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Aurora Daljit Singh | NMRA | See Remarks | Nov 11, 2025 | Sell | $2.68 | 114,703 | $307,025.52 | 0 | |
| Burow Kristina | NMRA | Director, 10% Owner | Oct 27, 2025 | Buy | $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 | |
| ARCH Venture Partners XII, LLC | NMRA | 10% Owner | Oct 27, 2025 | Buy | $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 | |
| ARCH Venture Partners X, LLC | NMRA | 10% Owner | Oct 27, 2025 | Buy | $2.61 | 1,915,700 | $4,999,977.00 | 6,046,907 |
See how NMRA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "NMRA Neumora Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.